Settlement reached on state Medicaid denial of pricey hep C drugs

Smoking declines dramatically but linked to 40 percent of cancer cases
November 29, 2016
Multiple Sclerosis Patients Would Be Helped by Palliative Care, Study Reports
November 29, 2016
Show all

Settlement reached on state Medicaid denial of pricey hep C drugs

A settlement was reached in a class action lawsuit that sought broader coverage of costly hepatitis C drugs for Medicaid patients in Washington state.

The Health Care Authority on Monday reached a settlement agreement in a class action lawsuit that sought broader coverage of costly hepatitis C drugs for Medicaid patients in Washington state.

The settlement has yet to be approved by a judge but lawyers are hopeful it will be soon.

In the past several years, multiple pharmaceutical companies nationwide have developed direct-acting antiviral drugs that cure hepatitis C in more than 90 percent of patients. But the drugs are extremely expensive – for example, Harvoni, introduced in 2014, has a list price of $1,100 a day, or $94,500 for a 12-week course. (After automatic drug rebates and other discounts, Medicaid pays about half that price for each patient.)

But under the state’s previous restrictions, Medicaid patients with hepatitis C could only access the expensive curative drugs if they had advanced liver disease, gauged by a “fibrosis” score, which measures the level of scarring on the liver.

Read Full Article: Settlement reached on state Medicaid denial of pricy hep C drugs | Local | yakimaherald.com

Read Full Article: Settlement reached on state Medicaid denial of pricy hep C drugs | Local | yakimaherald.com

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.